Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 19,410 Charles River Laboratories International, Inc. (NYSE:CRL)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 19,410 shares of the medical research company's stock, valued at approximately $3,583,000.

Several other large investors have also recently added to or reduced their stakes in CRL. Cornerstone Investment Partners LLC increased its holdings in Charles River Laboratories International by 3.7% in the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock valued at $358,000 after buying an additional 69 shares during the last quarter. Metis Global Partners LLC lifted its position in shares of Charles River Laboratories International by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock valued at $318,000 after acquiring an additional 72 shares during the period. Two Sigma Securities LLC lifted its position in shares of Charles River Laboratories International by 4.3% during the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after acquiring an additional 81 shares during the period. Wahed Invest LLC increased its stake in shares of Charles River Laboratories International by 6.5% during the 4th quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock worth $244,000 after purchasing an additional 81 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its stake in shares of Charles River Laboratories International by 16.3% during the 4th quarter. Jones Financial Companies Lllp now owns 641 shares of the medical research company's stock worth $118,000 after purchasing an additional 90 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president now directly owns 19,513 shares in the company, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

NYSE:CRL traded down $1.88 during trading hours on Thursday, reaching $141.34. 728,930 shares of the company's stock were exchanged, compared to its average volume of 994,788. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $6.94 billion, a P/E ratio of 942.25, a price-to-earnings-growth ratio of 4.54 and a beta of 1.48. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The business's 50-day simple moving average is $127.74 and its two-hundred day simple moving average is $159.23.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same quarter in the prior year, the firm earned $2.27 EPS. The company's revenue was down 2.7% compared to the same quarter last year. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CRL has been the subject of several recent analyst reports. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a research note on Wednesday, May 14th. Evercore ISI upgraded shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price on the stock in a report on Thursday, May 8th. Mizuho reduced their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Robert W. Baird boosted their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. Finally, The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Charles River Laboratories International has an average rating of "Hold" and a consensus price target of $171.85.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).